This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holmes, D. R. Search for Related Content PubMed PubMed Citation Articles by Holmes, D. R., Jr Related Collections Angioplasty and Stenting Related Article

(Circulation. 2004;109:2158-2159.)
© 2004 American Heart Association, Inc.

Focused Perspective

How Many Grails Do We Need?

David R. Holmes, Jr, MD

From the Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn.

Correspondence to David R. Holmes, Jr, MD, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail holmes.david@mayo.edu

Key Words: Focused Perspectives • restenosis • drugs

An extract of the first 250 words of the full text is provided, because this article has no abstract.

In a classic mixed metaphor of Greek and more recent continental lore, restenosis has been called the Achilles’ heel of interventional cardiology and the solution to restenosis has been called the holy grail. Restenosis itself has been the target of a multiplicity of initiatives, starting with trials of established drugs in the early 1980s, then moving more broadly to trials of many newer and different classes of drugs, and then finally to the application of a large number of widgets and gadgets. After initial promising animal trials and often small positive pilot human clinical experiences, larger scale randomized clinical trials were mounted only to fail the test of scientific trial design, the problems seemingly unmanageable.¹

See p 2168

The combination of drugs and devices in a single (albeit expensive) package has revolutionized the field. There are now abundant data from large scale well-designed clinical trials and even larger "real world" registries that have documented definitively that restenosis, although not completely abrogated, is dramatically improved with clinical restenosis rates in the lower to mid single digit range.^2,3 This formed the basis for the exceedingly rapid implementation of a specific drug-eluting stent code in the United States. The earliest and by far most robust data set is centered around sirolimus-eluting stents, which have been documented to be very safe and extremely effective in randomized blinded multicenter trials of selected patients, as well as in broader "real world" consecutive patient series.^{2, 4–9} More recently, paclitaxel-eluting stents have been approved,¹⁰ and they also result in . . . [Full Text of this Article]

Related Article:

Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer

Eberhard Grube, Shinjo Sonoda, Fumiaki Ikeno, Yasuhiro Honda, Saibal Kar, Charles Chan, Ulrich Gerckens, Alexandra J. Lansky, and Peter J. Fitzgerald
Circulation 2004 109: 2168-2171. [Abstract] [Full Text]

This article has been cited by other articles:

				Drug-Eluting Stent with a Bioabsorbable Polymer -- The Next Big Thing? Journal Watch Cardiology, July 9, 2004; 2004(709): 2 - 2. [Full Text]